Rosen JC, Sacher A, Tsao MS. Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg. Ther Adv Med Oncol. 2023;15:17588359231160141.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solanki HS, Welsh EA, Fang B, Izumi V, Darville L, Stone B, et al. Cell type-specific adaptive signaling responses to KRASG12C inhibition. Clin Cancer Res. 2021;27:2533–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12:217–37.

Article  PubMed  PubMed Central  Google Scholar 

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015;10:431–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288–300.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ricciuti B, Mira A, Andrini E, Scaparone P, Michelina SV, Pecci F, et al. How to manage KRAS G12C-mutated advanced non-small-cell lung cancer. Drugs Context. 2022;11:2022–7–4.

Article  PubMed  PubMed Central  Google Scholar 

Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garassino MC, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011;22:235–7.

Article  CAS  PubMed  Google Scholar 

Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC. FDA, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc Accessed 3 Aug 2024.

ESMO. FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC, https://www.esmo.org/oncology-news/fda-grants-accelerated-approval-to-adagrasib-for-kras-g12c-mutated-nsclc Aaccessed 5 Aug 2024.

Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, et al. Single-Agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023;389:710–21.

Article  CAS  PubMed  Google Scholar 

Fujiwara Y, Burns T, Dragnev K, Murciano-Goroff Y, Lee D, Hollebecque A, et al. Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC. J Clin Oncol. 2024;42:195–195.

Article  Google Scholar 

Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14:994–1017.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nokin MJ, Mira A, Patrucco E, Ricciuti B, Cousin S, Soubeyran I, et al. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nat Commun. 2024;15:7554.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mikubo M, Inoue Y, Liu G, Tsao MS. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J Thorac Oncol. 2021;16:1798–809.

Article  CAS  PubMed  Google Scholar 

Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170:564–76.e16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chakraborty A, Hanson L, Robinson D, Lewis H, Bickerton S, Davies M, et al. AZD4625 is a potent and selective inhibitor of KRASG12C. Mol Cancer Ther. 2022;21:1535–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kettle JG, Bagal SK, Bickerton S, Bodnarchuk MS, Boyd S, Breed J, et al. Discovery of AZD4625, a covalent allosteric inhibitor of the mutant GTPase KRASG12C. J Med Chem. 2022;65:6940–52.

Article  CAS  PubMed  Google Scholar 

Mirhadi S, Tam S, Li Q, Moghal N, Pham N-A, Tong J, et al. Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. Nat Commun. 2022;13:1811.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, et al. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer. 2017;140:662–73.

Article  CAS  PubMed  Google Scholar 

Shi R, Radulovich N, Ng C, Liu N, Notsuda H, Cabanero M, et al. Organoid cultures as preclinical models of non-small cell lung cancer. Clin Cancer Res. 2020;26:1162–74.

Article  PubMed  Google Scholar 

John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res. 2011;17:134–41.

Article  CAS  PubMed  Google Scholar 

Rosen JC, Weiss J, Pham NA, Li Q, Martins-Filho SN, Wang Y, et al. Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. Transl Oncol. 2021;14:101179.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED, et al. Xenome—a tool for classifying reads from xenograft samples. Bioinformatics. 2012;28:i172–178.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.

Article  PubMed  PubMed Central  Google Scholar 

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. cels. 2015;1:417–25.

CAS  Google Scholar 

Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis. bioRxiv 2021. https://doi.org/10.1101/060012.

Krieger JR, Wybenga-Groot LE, Tong J, Bache N, Tsao MS, Moran MF. Evosep one enables robust deep proteome coverage using tandem mass tags while significantly reducing instrument time. J Proteome Res. 2019;18:2346–53.

Article  CAS  PubMed  Google